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Conclusions. These findings indicate that BMP-7 treatmentTreatment of a murine model of high-turnover renal osteodys-
in the setting of high turnover renal osteodystrophy preventstrophy by exogenous BMP-7.
the development of peritrabecular fibrosis, affects the osteo-Background. The secondary hyperparathyroidism of chronic
blast phenotype and mineralizing surfaces, and decreases bonekidney disease (CKD) produces a high turnover osteodystro-
resorption. This is compatible with a role of osteoblast differen-phy that is associated with peritrabecular fibrosis. The nature
tiation in the pathophysiology of osteitis fibrosa.of the cells involved in the development of peritrabecular fi-
brosis may represent osteoprogenitors expressing a fibroblastic
phenotype that are retarded from progressing through osteo-
blast differentiation.
The term renal osteodystrophy is used to describe theMethods. To test the hypothesis that osteoblast differentia-
wide spectrum of skeletal abnormalities found in patientstion is retarded in secondary hyperparathyroidism due to CKD
producing bone marrow fibrosis, we administered bone mor- with chronic kidney disease (CKD) that ranges from states
phogenetic protein 7 (BMP-7), a physiologic regulator of os- of high bone turnover to states of low bone turnover [1, 2].
teoblast regulation, to C57BL6 mice that had CKD produced Histologically, high-turnover renal osteodystrophy, oftenby electrocautery of one kidney followed by contralateral ne-
referred to as osteitis fibrosa, is characterized by increasedphrectomy two weeks later. Following the second surgical pro-
numbers of osteoblasts as well as increased bone forma-cedure, a subgroup of mice received daily intraperitoneal injec-
tions of BMP-7 (10g/kg). Three to six weeks later, the animals tion rate and osteoid accumulation. Similarly, there are
were sacrificed, blood was obtained for measurements of blood increased number of osteoclasts and increased bone re-
urea nitrogen (BUN) and parathyroid hormone (PTH) levels, sorption [3]. In addition to these findings, there is fibrosisand the femora and tibiae were processed for histomorpho-
in the peritrabecular bone marrow space, the etiologymetric analysis.
of which has remained elusive [4, 5]. Clinically, the accu-Results. The animals had significant renal insufficiency with
BUN values of 77.79  22.68 mg/dL, and the level of renal mulation of fibrous tissue in the bone marrow in patients
impairment between the CKD untreated mice and the CKD with secondary hyperparathyroidism is a well recognized
mice treated with BMP-7 was the same in the two groups. PTH
cause of anemia and may significantly impair the re-levels averaged 81.13  51.36 and 75.4  43.61 pg/mL in the
sponse to erythropoietin [6–8].CKD and BMP-7 treated groups, respectively. The animals
with CKD developed significant peritrabecular fibrosis. In addi- In normal circumstances, bone marrow fibroblasts
tion, there was an increase in osteoblast surface and osteoid may develop from pluripotential mesenchymal stem
accumulation as well as increased activation frequency and cells, which can give rise to a number of committed and
increased osteoclast surface consistent with high turnover renal
restricted cell lineages including adipocytes, myocytesosteodystrophy. Treatment with BMP-7 eliminated peritrabe-
and osteoblasts as well as fibroblasts [9, 10]. However,cular fibrosis, increased osteoblast number, osteoblast surface,
mineralizing surface and single labeled surface. There was also in high-turnover renal osteodystrophy, there may be dys-
a significant decrease in the eroded surface induced by treat- regulation of the pathways leading to osteoblast and
ment with BMP-7. fibroblast differentiation in a direction that favors the
accumulation of collagen secreting cells in the peritra-
becular bone marrow [11, 12]. In this regard, we focusedKey words: chronic kidney disease, renal osteodystrophy, osteitis fi-
brosa, bone morphogenetic protein 7, secondary hyperparathyroidism. on one of the key regulators of osteoblast development,
the bone morphogenetic proteins (BMPs), which belongReceived for publication July 5, 2001
to the transforming growth factor- (TGF-) superfam-and in revised form September 25, 2001
Accepted for publication November 2, 2001 ily and have a wide variety of biological functions [13, 14].
The bone morphogenetic proteins were originally iso- 2002 by the International Society of Nephrology
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lated from bone extracts that were capable of inducing zine, ketamine and calcein were obtained from Sigma-
new bone formation at ectopic sites [15]. In vitro, the Aldrich Company (St. Louis, MO, USA). The study pro-
BMPs have been demonstrated to favor the development tocol was approved by the institutional animal care
of osteoblastic cells from undifferentiated precursors committee.
[16–19]. The actions of the bone morphogenetic proteins
are mediated by a transmembrane receptor complex con- Induction of chronic kidney disease and
sisting of a BMP type I and a type II receptor that have treatment protocol
serine threonine kinase activity [13, 20]. The binding of Four-week-old male C57/BL6 mice were allowed to
ligand to the BMP receptor results in phosphorylation
acclimatize for one week. CKD was induced by the pro-of Smad proteins, which are then translocated to the
cedure previously described by Gagnon and Gallimorenucleus where they regulate the expression of BMP re-
[33]. Briefly, CKD is achieved after two surgical proce-sponsive genes [13, 21].
dures. The first procedure involved electrocautery of theOne of the bone morphogenetic proteins, BMP-7, also
right kidney. The mice were anesthetized by administer-known as osteogenic protein 1 (OP-1) is highly expressed
ing ketamine (150 mg/kg) and xylazine (7.4 mg/kg) IP.in the adult kidney, and circulates in the bloodstream.
A 2-cm right flank incision was made and the right kidneyTherefore, it is possible that decreases in renal mass
was identified. The perirenal fat and adrenal gland werecould result in decreased BMP-7 production [22, 23]. As
separated from the kidney by blunt dissection and theis the case with several of the BMPs, BMP-7 has been
shown to induce osteoblast growth and differentiation kidney was exposed. The entire cortex of the right kidney
in vitro [24–26]. In experimental animals, BMP-7 has was cauterized except for a 2 mm area around the hilum.
been shown to induce ectopic bone formation as well as The kidney was returned to the renal fossa and the subcu-
to heal bone defects [26–29]. The osteogenic properties taneous tissues were sutured with 3-0 silk. The skin was
of this protein have been explored in the orthopedic closed using surgical clips. The mice were fed regular
arena, and studies in humans have confirmed that exoge- chow (Harlan Teklad, Madison, WI, USA) and were
nous BMP-7 can generate new bone and aid in the heal- allowed water ad libitum for two weeks and were then
ing of fractures [28]. BMP-7 deficient mice have develop- subjected to a left nephrectomy. The left kidney was
mental defects of the skeleton, kidneys and eyes, and exposed by the same procedure described above, the
die shortly after birth [30–32]. The effects of BMP-7
hilum was ligated using 6-0 silk and the kidney was ex-
deficiency in adult skeletal remodeling have not been
cised. The wound was closed as described above. Follow-clarified. As mentioned above, in the normal situation,
ing the second surgical procedure, the animals were ran-BMP-7 favors the differentiation of osteoblasts from
domized into two groups. One group received dailymesenchymal stem cells. Considering that BMP-7 is ex-
intraperitoneal injections of BMP-7 at a dose of 10 g/kgpressed in the kidney and is important in osteoblast
(CKDBMP-7), and the second group received no treat-development and function, in CKD one may expect an
ment (CKD). Normal mice were used as controls ataccumulation of osteoblast precursors as a result of para-
the request of the Animal Care Committee, since pilotthyroid hormone (PTH) stimulation of osteoprogenitors.
studies demonstrated no difference between normal andThese progenitors may be unable to differentiate into
sham operated/vehicle injected controls. The animals re-mature osteoblasts because of BMP-7 deficiency. Alter-
ceived regular mouse chow and water at libitum for thenatively, in the setting of decreased BMP-7 production
by the kidney, the mesenchymal stem cells may be con- duration of the studies. Animals were sacrificed after 3,
strained from differentiating along the osteoblast path- 4 or 6 weeks of CKD. Blood samples were obtained by
way, and therefore may differentiate along an alternate intracardiac puncture at the time of sacrifice for blood
pathway, the fibroblast pathway. In either situation, the urea nitrogen (BUN) and PTH levels in each group of
subsequent accumulation of fibrous cells could then offer animals. Five animals were sacrificed after 3 weeks and
an explanation for the marrow fibrosis observed in sec- were used for histological analysis. Eighteen CKD ani-
ondary hyperparathyroidism in the setting of CKD. The mals (10 CKD untreated, 8 CKD  BMP-7 and 3 con-
present studies examined the effect of BMP-7 on the trols) were sacrificed 4 weeks post-nephrectomy after
development of peritrabecular fibrosis in a murine model receiving calcein labeling (see histomorphometry) and
of CKD.
were analyzed for all histomorphometry parameters ex-
cept fibrous volume. Ten CKD mice (5 CKD treated
METHODS and 5 CKD  BMP-7) were sacrificed 6 weeks post-
nephrectomy for analysis of fibrous volume. Results ob-Male C57/BL6 mice were purchased from Harlan
tained from each group are shown and indicated in the(Indianapolis, IN, USA). BMP-7 was provided by Cre-
ative BioMolecules, Inc. (Hopkinton, MA, USA). Xyla- text and Figures as appropriate.
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Fig. 1. Blood urea nitrogen (BUN) and intact
parathyroid hormone (PTH) levels in mice
with chronic renal insufficiency. Chronic kid-
ney disease (CKD) was induced in male C57/
BL6 mice by electrocautery of one kidney fol-
lowed by contralateral nephrectomy two weeks
later. The mice were 7 weeks old at the time of
induction of renal failure and were sacrificed 3
to 6 weeks later. Blood urea nitrogen (A) and
intact PTH levels (B) were determined in sam-
ples obtained by cardiac puncture at the time
of sacrifice (N 8, 15 and 11 for control, CKD
and CKD  BMP-7 groups, respectively).
Values represent mean  SD. * P  0.01 for
CKD groups as compared to controls.
Measurements of parathyroid hormone and Calculations
blood urea nitrogen Statistical analyses were performed using the Student
Blood samples were obtained by intracardiac puncture t test. Differences between groups were considered sig-
at the time of sacrifice and transferred to heparinized nificant when P  0.05. Data are expressed as means 
tubes. After centrifugation (400  g for 10 min), plasma standard deviation.
was removed, aliquoted and frozen at80	C. Intact PTH
levels were measured by two-site immunoradiometric RESULTS
assay (IRMA) using a commercially available kit (Im-
Evaluation of renal insufficiencymutopics, San Clemente, CA, USA). BUN was mea-
sured using a commercially available kit (INFINITY Blood urea nitrogen levels were used to assess renal
BUN Reagent; Sigma Diagnostics, St. Louis, MO, USA). function. The levels in normal mice averaged 30.53 
3.52 mg/dL and in CKD mice averaged 77.79  22.68
Bone histology and histomorphometry mg/dL (P  0.05). As shown in Figure 1A, BUN levels
For in vivo fluorescent labeling, the mice received IP in animals with CKD treated with BMP-7 (N  11)
calcein 20 mg/kg seven and two days prior to sacrifice were not different from animals with CKD that had
four weeks after nephrectomy. Tibiae and femora were not received treatment (N 15), (BUN 74.26 22.59
dissected at the time of sacrifice and placed in buffered and 80.38 23.17 mg/dL in BMP-7 treated vs. untreated
formalin. The specimens were dehydrated in a series of CKD mice, P  0.51). There was also no difference in
graded ethanol solutions, and implanted undecalcified the BUN between CKD animals sacrificed at differ-
in a plastic embedding kit H7000 (Energy Beam Sci- ent time points (data not shown). Consistent with previ-
ences, Inc., Agawam, MA, USA). Bones were sectioned ous studies, we found that this model of CKD results in
longitudinally through the frontal plane in 5 m sections growth retardation [33]. Thus, prior to the induction of
with a JB-4 Microtome (Energy Beam Sciences, Inc.). CKD, the weights averaged 15.53  1.25 g, and 4 weeks
Tissue was stained with Goldner’s trichrome stain for later there was no significant change in the CKD mice
trabecular and cellular analysis. TRAP staining was used (16.02  1.55 g, P  NS), whereas a significant increase
to identify osteoclasts and define osteoclast surfaces. Un- in weight was noted in the control animals during the
stained 10 m sections were used for calcein-labeled same time period (18.37  0.96 g, P  0.005). Treat-
fluorescence analysis. A reticulin stain was used in the ment with BMP-7 did not have an effect on body weight
animals sacrificed six weeks after nephrectomy for analy- (15.33  1.60 g vs. 16.58  1.34 g in CKD mice treated
sis of peritrabecular fibrosis. Slides were examined at with BMP-7 vs. CKD untreated mice, respectively,
400 magnification using a Leitz microscope attached P  NS).
to an Osteomeasure Image Analyzer (Osteometrics, At-
Assessment of secondary hyperparathyroidismlanta, GA, USA). Ten contiguous 0.0225 mm2 fields of
the proximal tibia, 150 m distal to the growth plate As shown in Figure 1B, intact PTH levels in normal
mice averaged 25.00  16.20 pg/mL. Animals with CKD(to exclude secondary spongiosum), were examined per
animal. Primary, derived and kinetic measures of bone developed significant secondary hyperparathyroidism
with average intact PTH levels of 81.61  50.62 pg/mLremodeling were calculated and reported per the guide-
lines of the American Society of Bone and Mineral (P  0.0025 vs. controls). Treatment with BMP-7 did
not have a significant effect on the levels of intact PTHResearch [34].
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Fig. 2. Effect of BMP-7 on bone histology in mice with chronic kidney disease. Representative histological sections of proximal tibia from control
mice, CKD mice and CKD mice treated with BMP-7 (50 and 100 magnification in A and B, respectively). The mice were 7-weeks-old at the
time of induction of renal failure and were sacrificed 3 weeks later. Note increased trabecular bone (blue) and decreased marrow space (red) as
well as the fibrous appearance of the marrow space in the CKD untreated animals. The histologic abnormalities in the CKD mice treated with
BMP-7 are markedly less pronounced.
(75.45  43.61 pg/mL vs. 86.13 51.36 pg/mL in BMP-7 Effect of treatment with BMP-7 on bone histology
treated vs. untreated mice, P  0.58). There was no Histologic analysis of bone sections demonstrated that
significant difference in the intact PTH levels between animals with CKD developed significant osteodystrophy
CKD animals sacrificed at different time points (data as illustrated in Figure 2 (low and high power). In the
bones of mice with CKD there was less cortical bonenot shown).
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Fig. 3. Effect of BMP-7 treatment in murine renal osteodystrophy.
Photomicrographs at400 power of trabecular bone (TB) in the proxi-
mal tibia in normal control (A), CKD (B) and CKD mice treated with
BMP-7 (C ) stained with Goldner’s stain. Unmineralized osteoid (→)
is prominent in both the CKD and the BMP-7 treated animals, compared
to the control. Osteoclasts (➤) are present in resorption lacunae. Osteo-
blasts (➜) in the control and BMP-7 treated group have greater cell
height compared to the CKD group. Representative sections were se-
lected to illustrate osteoid and osteoblast layers.
Fig. 8. Effect of BMP-7 treatment on marrow fibrosis in murine renal osteodystrophy. Reticulin stained specimens at 400 magnification of
trabecular bone (TB) in the marrow cavity of the proximal tibia showing significant fibrosis (F) in the marrow cavity of CKD animals (A) consistent
with osteitis fibrosa. This fibrosis is eliminated in uremic animals treated with BMP-7 (B). Osteoblasts (➜) in the BMP-7 treated group have a
more cuboidal morphology compared to the CKD group.
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Fig. 4. Effect of BMP-7 treatment on the cellular surfaces of trabecular bone in mice with chronic kidney disease. Histomorphometric analysis
in control mice (N  3), CKD untreated mice (N  10), and CKD mice treated with BMP-7 (N  8). The mice were 7 weeks old at the time of
induction of renal failure and were sacrificed 4 weeks later. There was an increase in osteoid surface in the CKD animals (A), which was not
affected by BMP-7 treatment. Note the increases in osteoclast (B) and eroded surface (C ) and osteoclast number (D) in CKD animals. BMP-7
treatment increased the osteoblast surface (E ) and osteoblast number (F ), and it also decreased the eroded surface (C ). Values represent mean 
SD. * Significant (P  0.05) difference between either of the CKD groups and the control group; † Significant difference between the CKD group
and the BMP-7 treated group.
as compared to controls; however, there was increased turnover osteodystrophy as evidenced by significantly
increased osteoid surface (OS/BS 10.6% in control vs.trabecular bone present, and the marrow space was de-
creased. In addition, there was substantial marrow fibro- 39.7% in CKD mice; Fig. 4A), increased osteoclast sur-
face (OcS/BS 10.5% in control vs. 20.4% in CKD mice;sis surrounding the trabeculae in the CKD group and
the marrow space was occupied by a population of cells Fig. 4B), increased eroded surface (ES/BS 19.8% in con-
trol vs. 34.6% in CKD mice; Fig. 4C) and increasedwith a fibrous appearance. The histologic findings in the
bones of the animals with CKD that received BMP-7 osteoclast number (NOc 12 in control vs. 21.2 in CKD
mice; Fig. 4D). In addition to the changes in the cellulardiffered from those of the untreated animals in that the
alterations observed in trabecular bone, cortical bone as surfaces of trabecular bone CKD was associated with
decreased mineralizing surfaces (MS/OS 365% in controlwell as the fibrous changes were markedly less pro-
nounced. vs. 103% in CKD mice) (Fig. 5A) and a decreased wall
thickness (WTh 6.66 m in control vs. 4.25 m in CKD
Effect of treatment with BMP-7 on mice; Fig. 5C), resulting in an increased Activation Fre-
bone histomorphometry quency (Acf 9.93/year in control vs. 17.9/year in CKD
mice; Fig. 6). Treatment with BMP-7 increased the osteo-Representative fields of proximal tibial trabecular
bone stained with Goldner’s trichrome stain in normal blast surface (Fig. 4E), increased the osteoblast number
(Fig. 4F) and decreased the eroded surface (Fig. 4C). Incontrol animals (A), animals with CKD (B) and animals
with CKD treated with BMP-7(C) are shown in Figure 3. addition, BMP-7 eliminated the significant increase in
osteoclast surface (Fig. 4B) and osteoclast number (Fig.The animals with CKD had findings consistent with high
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Fig. 5. Effect of BMP-7 treatment on trabecular mineralization in mice with chronic kidney disease. Dynamic histomorphometry in control mice
(N  3), CKD untreated mice (N  10), and CKD mice treated with BMP-7 (N  8). The mice were 7 weeks old at the time of induction of
renal failure and were sacrificed 4 weeks later. Fluorescent calcein 20 mg/kg was administered intraperitoneally seven and two days prior to sacrifice.
Note the decreased mineralizing surface (A) in CKD animals, which was improved with BMP-7 treatment, the significant increase in single labeled
surface (B) and the improvement in wall thickness (C ) with BMP-7 treatment. Values represent mean  SD. * Significant (P  0.05) difference
between either of the CKD groups and the control group; †significant difference between the CKD group and the BMP-7 treated group.
Fig. 6. Effect of BMP-7 treatment on rates of bone turnover in murine Fig. 7. Effect of BMP-7 treatment on marrow fibrosis in murine renal
renal osteodystrophy. Activation frequency (the probability that a new osteodystrophy. Fibrous volume per total volume (%) was determined
cycle of remodeling will be initiated at any point on the bone surface) in mice treated (N  5) or untreated (N  5) with BMP-7 since the time
in control mice (N  3), CKD untreated mice (N  10), and CKD of induction of CKD. The mice were 7 weeks old at the time of induction
mice treated with BMP-7 (N  8). The mice were 7 weeks old at the of renal failure and were sacrificed 6 weeks later. Note the marked
time of induction of renal failure and were sacrificed 4 weeks later. volume of fibrosis in the CKD animals, which was prevented by treat-
Note the increased activation frequency in the uremic animals consistent ment with BMP-7. Values represent mean SD. * Significant (P 0.05)
with high turnover renal osteodystrophy. Values represent mean SD. difference between the CKD group and the control group; † Significant
* Significant (P  0.05) difference between the CKD group and the difference between the CKD group and the BMP-7 treated group.
control group.
ization by increasing mineralizing surface (Fig. 5A), in-
4D) observed in the CKD mice compared to the controls; creasing single labeled surface (Fig. 5B) and increasing
however, the changes induced by BMP-7 were of small wall thickness compared to CKD (Fig. 5C). There was
magnitude and not statistically significant from the CKD no significant change in activation frequency (Fig. 6). As
shown graphically in Figure 7 and at400 magnificationuntreated animals. BMP-7 affected trabecular mineral-
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Table 1. Additional histomorphology data of trabecular bone in the proximal tibia (not included in Figs. 4–7),
between normal control mice (N  3), CKD mice (N  10), and CKD mice treated with BMP-7 (N  8) for 4 weeks
Normal CKD CKDBMP-7
Bone surface BS/TV mm2/mm3 17.271.06 18.742.79 17.313.33
Trabecular thickness TbTh m 37.345.19 41.619.12 39.915.54
Trabecular number TbN /mm 8.630.53 9.351.37 8.661.67
Mineralizing surface MS/BS % 37.563.2 38.395.14 49.244.9ab
Double labeled surface dLS/BS % 11.241.46 8.513.32 9.953.13
Bone formation rate BFR/BS m3/m2/year 66.5618.51 75.7817.98 86.8636.16
Values represent mean  SD.
a Significant (P  0.05) difference between the CKD  BMP-7 group and the control group
b Significant difference between the CKD group and the BMP-7 treated group
in Figure 8, a significant peritrabecular fibrosis was pres- thyroidism. Studies in experimental animals exposed to
continuous PTH administration also have described theent in the bones of animals with CKD, which was largely
presence of fibroblastic cells in trabecular bone [36]. Theprevented by treatment with BMP-7 (FbV/TV 3.65% in
mechanisms involved in the accumulation of fibroblasticCKD mice vs. 0.79% in CKD mice treated with BMP-7,
cells in states of parathyroid hormone excess have re-P  0.0065). Additional parameters of histomorpho-
mained poorly understood. Recent studies by Calvi etmetry are shown in Table 1.
al [12] with mice expressing a constitutively active PTH/
PTHrP receptor in cells of the osteoblastic lineage, as
DISCUSSION described in patients with Jansen’s metaphyseal chon-
Renal osteodystrophy is a common complication en- drodysplasia [37], demonstrated features of hyperpara-
countered in patients with chronic kidney disease, and thyroid bone disease including marrow fibrosis. The fi-
secondary hyperparathyroidism as a result of chronic brous cells were found to express a number of osteoblast
kidney disease plays an important role in the genesis of markers including osteopontin, alkaline phosphatase and
high turnover renal osteodystrophy [1, 2, 35]. In addition collagenase, thus suggesting that these cells represent
to increased osteoclastic bone resorption and osteoblas- osteoblast precursors unable to fully differentiate into
tic bone formation, the skeletal lesion of hyperparathy- mature osteoblasts. Marrow fibrosis is also a feature of
roidism, osteitis fibrosa, is characterized by the presence fibrous dysplasia of bone, a condition resulting from acti-
of bone marrow fibrosis, the etiology of which remains vating mutations of the gene encoding the 
 subunit of
poorly understood. We hypothesized that the marrow the stimulatory G protein [38–40]. The cells associated
fibrosis of hyperparathyroid bone disease in CKD may with this lesion also appear to be constrained from dif-
result from the lack of osteoblast differentiation factors ferentiation into mature osteoblasts [11]. The mecha-
possibly due to their decreased production by the failing nism for the failure of these osteoblast progenitors to
kidney. Thus, we studied the effects of BMP-7 adminis- progress normally through the osteoblast differentiation
tration (a factor made in the kidney known to regulate program is not clear, although PTH has been shown to
osteoblast differentiation) to mice with chronic kidney be insufficient in directing osteoblast differentiation in
disease. The degree of renal impairment created by the vitro [41, 42].
electrocautery and contralateral nephrectomy model is The present studies demonstrate that exogenous ad-
clinically stable over time (Hruska, unpublished data), ministration of an osteoblast differentiation factor, BMP-7,
and not a progressive model of renal disease. Similarly, to animals with CKD and secondary hyperparathyroid-
the degree of hyperparathyroidism remained stable in ism prevents the development of marrow fibrosis and
these studies; however, we do not have information on the accumulation of fibrous cells in the bone marrow.
the progression of secondary hyperparathyroidism be- Since there is evidence to suggest that the cells that
yond six weeks of CKD. We found that mice with CKD accumulate in the bone marrow in osteitis fibrosa repre-
developed secondary hyperparathyroidism and high sent poorly differentiated osteoblasts [11, 12], the accu-
turnover osteodystrophy with peritrabecular fibrosis. mulation of these cells in the setting of secondary hyper-
Administration of BMP-7 virtually prevented the devel- parathyroidism due to CKD may be the result of two
opment of marrow fibrosis and produced significant in- abnormalities related to the uremic setting. On the one
creases in mineralizing osteoblast surfaces, osteoblast hand, excess PTH has been suggested to increase the
number and morphology. proliferation of osteoprogenitors [41, 42] and on the
Parathyroid hormone excess has long been recognized other hand, lack of BMP-7, as a result of decreased renal
to be associated with the development of marrow fibrosis mass, may inhibit the differentiation of osteoprogenitors
into mature osteoblasts. Thus, it appears that by adminis-in humans with either primary or secondary hyperpara-
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6th ed), edited by Brenner BM, Philadelphia, W.B. Saunders Com-tering exogenous BMP-7, the osteoprogenitors fail to
pany, 2000, pp 2103–2186
accumulate because they are now capable of differentiat- 3. Malluche H, Ritz E, Lange H: Bone histology in incipient and
advanced renal failure. Kidney Int 9:355–362, 1976ing into mature osteoblasts. An alternative explanation
4. Nomura S, Ogawa Y, Osawa G, et al: Myelofibrosis secondaryfor the accumulation of fibrous cells in high-turnover
to renal osteodystrophy. Nephron 72:683–687, 1996
renal osteodystrophy may be that in a state of BMP-7 5. Weinberg SG, Lubin A, Wiener SN, et al: Myelofibrosis and renal
osteodystrophy. Am J Med 63:755–764, 1977deficiency, the pluripotential mesenchymal stem cells are
6. Barbour GL: Effect of parathyroidectomy on anemia in chronicinhibited from differentiating into osteoprogenitors, and
renal failure. Arch Intern Med 139:889–891, 1979
therefore enter an alternative differentiation pathway 7. Rao DS, Shih MS, Mohini R: Effect of serum parathyroid hormone
and bone marrow fibrosis on the response to erythropoietin inand give rise to cells with a fibroblastic phenotype.
uremia. N Engl J Med 328:171–175, 1993The present studies clearly demonstrate that CKD and
8. Gallieni M, Corsi C, Brancaccio D: Hyperparathyroidism and
secondary hyperparathyroidism produce abnormalities anemia in renal failure. Am J Nephrol 20:89–96, 2000
9. Golde DW, Hocking WG, Quan SG, et al: Origin of human bonein osteoblast differentiation reflected by accumulation
marrow fibroblasts. Br J Haematol 44:183–187, 1980of fibrous tissue producing cells as well as increased os-
10. Lian JB, Stein GS, Canalis E, et al: Bone formation: Osteoblast
teoclast activity. BMP-7 eliminated the fibrous producing lineage cells, growth factors, matrix proteins, and the mineraliza-
tion process, in Primer on The Metabolic Bone Diseases and Disor-cells and increased osteoblast number demonstrating im-
ders of Mineral Metabolism (4th ed), edited by Favous MJ, Philadel-proved osteoblast differentiation in CKD. The effects of
phia, Lippincott Williams & Wilkins, 1999, pp 14–29
BMP-7 treatment on osteoclasts were unexpected and 11. Bianco P, Kuznetsov SA, Riminucci M, et al: Reproduction of
human fibrous dysplasia of bone in immunocompromised micethe mechanisms involved remain to be determined.
by transplanted mosaics of normal and Gsalpha-mutated skeletalIn summary, using an animal model of high-turnover
progenitor cells. J Clin Invest 101:1737–1744, 1998
renal osteodystrophy, the present studies demonstrate 12. Calvi LM, Sims NA, Hunzelman JL, et al: Activated parathyroid
hormone/parathyroid hormone-related protein receptor in osteo-that treatment with BMP-7 prevents the development
blastic cells differentially affects cortical and trabecular bone. J Clinof marrow fibrosis. These findings suggest that the bone
Invest 107:277–286, 2001
marrow fibrosis characteristic of secondary hyperpara- 13. Rosen V, Cox K, Hattersley G: Bone morphogenetic proteins,
in Principles of Bone Biology, edited by Bilezikian JP, Raisz LG,thyroidism in chronic kidney disease may represent the
Rodan GA, San Diego, Academic Press, Inc., 1996, pp 661–671actions of cells constrained from osteoblast differentia- 14. Ducy P, Karsenty G: The family of bone morphogenetic proteins.
tion, perhaps as a consequence of BMP-7 deficiency. Kidney Int 57:2207–2214, 2000
15. Urist MR: Bone: Formation by autoinduction. Science 150:893–Additional studies on the cellular abnormalities involved
899, 1965in the generation of marrow fibrosis in high-turnover 16. Wang EA, Israel DI, Kelly S, Luxenberg DP: Bone morpho-
renal osteodystrophy will further clarify the mechanisms genetic protein-2 causes commitment and differentiation in C3H-
10T1/2 and 3T3 cells. Growth Factors 9:57–71, 1993involved in this process, and aid in the development
17. Thies RS, Bauduy M, Ashton BA, et al: Recombinant humanof therapeutic interventions. The prevention of marrow bone morphogenetic protein-2 induces osteoblastic differentiation
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